Literature DB >> 19079272

Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls.

Giuseppe Costante1, Cosimo Durante, Zélia Francis, Martin Schlumberger, Sebastiano Filetti.   

Abstract

An elevated serum calcitonin level is a highly sensitive marker for medullary thyroid carcinoma (MTC) that can be used for screening, differential diagnosis, prognostic assessment, follow-up monitoring, and assessment of treatment response. Nevertheless, additional data are required to definitively support routine measurement of calcitonin levels in the initial work-up of patients with thyroid nodules, mainly because there is no convincing evidence that such testing actually reduces MTC-related mortality. By contrast, the prognostic value of measuring calcitonin levels preoperatively, postoperatively, and during follow-up of patients with MTC is widely acknowledged. Furthermore, determination of calcitonin levels is also used to evaluate the response of MTC to novel forms of systemic treatment, such as tyrosine kinase inhibitors. In this Review, we discuss the key issues surrounding the use of this laboratory test in the clinical management of patients with MTC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19079272     DOI: 10.1038/ncpendmet1023

Source DB:  PubMed          Journal:  Nat Clin Pract Endocrinol Metab        ISSN: 1745-8366


  59 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  THYROID ORIGIN OF CALCITONIN.

Authors:  G V FOSTER; A BAGHDIANTZ; M A KUMAR; E SLACK; H A SOLIMAN; I MACINTYRE
Journal:  Nature       Date:  1964-06-27       Impact factor: 49.962

Review 3.  Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors.

Authors:  K L Becker; E S Nylén; J C White; B Müller; R H Snider
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

4.  Increased calcitonin level in thyroid nodules without medullary carcinoma.

Authors:  H Gibelin; D Essique; C Jones; P Levillain; R Maréchaud; J-L Kraimps
Journal:  Br J Surg       Date:  2005-05       Impact factor: 6.939

5.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2008-08-05       Impact factor: 25.391

6.  "Hook effect" in calcitonin immunoradiometric assay in patients with metastatic medullary thyroid carcinoma: case report and review of the literature.

Authors:  Rébecca Leboeuf; Marie-France Langlois; Marc Martin; Charaf E Ahnadi; Guy D Fink
Journal:  J Clin Endocrinol Metab       Date:  2005-11-08       Impact factor: 5.958

7.  American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules.

Authors:  Hossein Gharib; Enrico Papini; Roberto Valcavi; H Jack Baskin; Anna Crescenzi; Massimo E Dottorini; Daniel S Duick; Rinaldo Guglielmi; Carlos Robert Hamilton; Martha A Zeiger; Michele Zini
Journal:  Endocr Pract       Date:  2006 Jan-Feb       Impact factor: 3.443

8.  Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders.

Authors:  H Vierhapper; B Niederle; C Bieglmayer; K Kaserer; S Baumgartner-Parzer
Journal:  Thyroid       Date:  2005-11       Impact factor: 6.568

Review 9.  Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma.

Authors:  Andreas Machens; Henning Dralle
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

Review 10.  Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature.

Authors:  José Miguel Dora; Maria Heloisa Busi da Silva Canalli; Clarissa Capp; Márcia Khaled Puñales; José Gilberto H Vieira; Ana Luiza Maia
Journal:  Thyroid       Date:  2008-08       Impact factor: 6.568

View more
  34 in total

1.  Early diagnosis of medullary thyroid carcinoma: is systematic calcitonin screening appropriate in patients with nodular thyroid disease?

Authors:  Giuseppe Costante; Sebastiano Filetti
Journal:  Oncologist       Date:  2011-01-06

2.  Identification of down-regulated microRNAs in thyroid cancer and their potential functions.

Authors:  Denghua Pan; Peng Lin; Dongyue Wen; Yunpeng Wei; Qiuyan Mo; Liang Liang; Gang Chen; Yun He; Junqiang Chen; Hong Yang
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

3.  Treating medullary thyroid carcinoma in a tertiary center. Current trends and review of the literature.

Authors:  E Prokopakis; M Doulaptsi; A Kaprana; S Velegrakis; Y Vlastos; G Velegrakis
Journal:  Hippokratia       Date:  2014-04       Impact factor: 0.471

Review 4.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

Review 5.  Calcitonin as a biomarker of C cell disease: recent achievements and current challenges.

Authors:  Giuseppe Costante; Domenico Meringolo
Journal:  Endocrine       Date:  2020-01-10       Impact factor: 3.633

6.  Metastatic neuroendocrine tumor of the esophagus with features of medullary thyroid carcinoma.

Authors:  Raymond M Fertig; Adam Alperstein; Carlos Diaz; Kyle D Klingbeil; Sameera S Vangara; Ryosuke Misawa; Jennifer Reed; Sudeep Gaudi
Journal:  Intractable Rare Dis Res       Date:  2017-08

Review 7.  Management of medullary thyroid carcinoma and MEN2 syndromes in childhood.

Authors:  Steven G Waguespack; Thereasa A Rich; Nancy D Perrier; Camilo Jimenez; Gilbert J Cote
Journal:  Nat Rev Endocrinol       Date:  2011-08-23       Impact factor: 43.330

8.  Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma.

Authors:  Dana T Yip; Maria Hassan; Kalliopi Pazaitou-Panayiotou; Daniel T Ruan; Atul A Gawande; Randall D Gaz; Francis D Moore; Richard A Hodin; Antonia E Stephen; Peter M Sadow; Gilbert H Daniels; Gregory W Randolph; Sareh Parangi; Carrie C Lubitz
Journal:  Surgery       Date:  2011-12       Impact factor: 3.982

Review 9.  Thyroid nodule guidelines: agreement, disagreement and need for future research.

Authors:  Ralf Paschke; Laszlo Hegedüs; Erik Alexander; Roberto Valcavi; Enrico Papini; Hossein Gharib
Journal:  Nat Rev Endocrinol       Date:  2011-03-01       Impact factor: 43.330

10.  The vitamin d receptor in thyroid development and function.

Authors:  Isabelle Clinckspoor; Anne-Catherine Gérard; Jacqueline Van Sande; Marie-Christine Many; Lieve Verlinden; Roger Bouillon; Geert Carmeliet; Chantal Mathieu; Annemieke Verstuyf; Brigitte Decallonne
Journal:  Eur Thyroid J       Date:  2012-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.